Publicaciones: febrero 2024

Systemic biomarker associated with poor outcome after futile reperfusion

Hervella P, Sampedro-Viana A et al.  Eur J Clin Invest. 2024 Feb 15:e14181. doi: 10.1111/eci.14181. Online ahead of print. PMID: 38361320

https://pubmed.ncbi.nlm.nih.gov/38361320/

Abstract:
Background: Successful recanalization does not lead to complete tissue reperfusion in a considerable percentage of ischemic stroke patients. This study aimed to identify biomarkers associated with futile recanalization. Leukoaraiosis predicts poor outcomes of this phenomenon. Soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK), which is associated with leukoaraiosis degrees, could be a potential biomarker.
Methods: This study includes two cohorts of ischemic stroke patients in a multicentre retrospective observational study. Effective reperfusion, defined as a reduction of ≥8 points in the National Institutes of Health Stroke Scale (NIHSS) within the first 24 h, was used as a clinical marker of effective reperfusion.

Funding; Spanish Ministry of Science and Innovation (SAF2017- 84267-R), PDC2021-121455-I00, Xunta de Galicia (Axencia Galega de Innovación: IN607A2022–03), Instituto de
Salud Carlos III (ISCIII) (PI17/00540, PI17/01103), ISCIII/PI21/01256/Co-financed by the European Union, Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS PLUS (RD16/0019/0001 and RD16/0019/0003), RICORS-ICTUS (Cerebrovascular diseases) RD21/0006/0003 and RD21/0006/0011. DTS/00103 (Desarrollo Tecnológico en Salud del ISCIII) M. BazarraBarreiros is a PFIS Researcher (FI22/00200) of Instituto de Salud Carlos III. T. Sobrino (CPII17/00027), F. Campos (CPII19/00020) and R. Iglesias-Rey (CP22/00061) from the Miguel Servet Program of Instituto de Salud Carlos III. Sponsors did not participate in the study design, collection, analysis, or interpretation of the data, or in writing the report.